instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Staphylococcal infection'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment noncompliance'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Viral load increased'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Viral mutation identified'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Virologic failure'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | ABACAVIR, AMIKACIN SULFATE, COBICISTAT, DARUNAVIR, DOLUTEGRAVIR, EMTRICITABINE, LAMIVUDINE, LEVOFLOXACIN, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the administration route of drug 'AMIKACIN SULFATE'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the administration route of drug 'AMIKACIN'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34844616 | 20,778,814 | 2021-11-29 |
What was the administration route of drug 'AZITHROMYCIN'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34844616 | 20,778,814 | 2021-11-29 |
What was the administration route of drug 'COBICISTAT'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Oral | DrugAdministrationRoute | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the administration route of drug 'DARUNAVIR'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Oral | DrugAdministrationRoute | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the administration route of drug 'DOLUTEGRAVIR'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Oral | DrugAdministrationRoute | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the administration route of drug 'EMTRICITABINE'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Oral | DrugAdministrationRoute | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the administration route of drug 'LEVOFLOXACIN'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34844616 | 20,778,814 | 2021-11-29 |
What was the administration route of drug 'TENOFOVIR DISOPROXIL FUMARATE'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Oral | DrugAdministrationRoute | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the outcome of reaction 'Drug ineffective for unapproved indication'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Fatal | ReactionOutcome | CC BY | 34844616 | 20,778,814 | 2021-11-29 |
What was the outcome of reaction 'Product use in unapproved indication'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Fatal | ReactionOutcome | CC BY | 34844616 | 20,778,814 | 2021-11-29 |
What was the outcome of reaction 'Protein-losing gastroenteropathy'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Fatal | ReactionOutcome | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the outcome of reaction 'Sepsis'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Fatal | ReactionOutcome | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the outcome of reaction 'Therapy non-responder'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Fatal | ReactionOutcome | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
What was the outcome of reaction 'Virologic failure'? | Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.
BACKGROUND
Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced hu... | Fatal | ReactionOutcome | CC BY | 34844616 | 20,741,170 | 2021-11-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diagnostic procedure'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hospitalisation'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertrichosis'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mucocutaneous disorder'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Onycholysis'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Palmar-plantar erythrodysaesthesia syndrome'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Paronychia'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyogenic granuloma'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash pustular'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin fissures'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Trichomegaly'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Xerosis'. | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | FILGRASTIM, PANITUMUMAB | DrugsGivenReaction | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
What was the outcome of reaction 'Death'? | Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
BACKGROUND
Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
OBJECTIVE
To evaluate the most common adverse e... | Fatal | ReactionOutcome | CC BY | 34844792 | 20,485,416 | 2021-11-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pruritus'. | Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in liver transplantation.
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare delayed-type hypersensitivity reaction that causes skin abnormalities and mucosal involvement of the entire body. This is a case report of DRE... | TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34845130 | 20,558,301 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in liver transplantation.
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare delayed-type hypersensitivity reaction that causes skin abnormalities and mucosal involvement of the entire body. This is a case report of DRE... | TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34845130 | 20,558,301 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tubulointerstitial nephritis'. | Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis.
OBJECTIVE
We examined whether advances in treatment strategies from older disease-modifying antirheumatic drugs (DMARDs) to new biologic agents and methotrexate improved rena... | TACROLIMUS | DrugsGivenReaction | CC BY | 34846624 | 20,866,069 | 2021-11-30 |
What was the dosage of drug 'TACROLIMUS'? | Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis.
OBJECTIVE
We examined whether advances in treatment strategies from older disease-modifying antirheumatic drugs (DMARDs) to new biologic agents and methotrexate improved rena... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 34846624 | 20,937,810 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Clinical Heterogeneity in Acute Symptomatic Seizures due to Autoimmune Encephalitis Related to GAD65 Antibodies.
BACKGROUND
This study aimed to explore the diversity and clinical features of acute symptomatic seizures due to autoimmune encephalitis related to anti-glutamate decarboxylase (GAD) 65 antibodies.
METHODS
... | METHYLPREDNISOLONE SODIUM SUCCINATE | DrugsGivenReaction | CC BY-NC | 34847555 | 20,189,306 | 2021-11-30 |
What was the administration route of drug 'METHYLPREDNISOLONE SODIUM SUCCINATE'? | Clinical Heterogeneity in Acute Symptomatic Seizures due to Autoimmune Encephalitis Related to GAD65 Antibodies.
BACKGROUND
This study aimed to explore the diversity and clinical features of acute symptomatic seizures due to autoimmune encephalitis related to anti-glutamate decarboxylase (GAD) 65 antibodies.
METHODS
... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34847555 | 20,189,306 | 2021-11-30 |
What was the dosage of drug 'METHYLPREDNISOLONE SODIUM SUCCINATE'? | Clinical Heterogeneity in Acute Symptomatic Seizures due to Autoimmune Encephalitis Related to GAD65 Antibodies.
BACKGROUND
This study aimed to explore the diversity and clinical features of acute symptomatic seizures due to autoimmune encephalitis related to anti-glutamate decarboxylase (GAD) 65 antibodies.
METHODS
... | 0.5-1 G, DAILY | DrugDosageText | CC BY-NC | 34847555 | 20,189,306 | 2021-11-30 |
What was the outcome of reaction 'Drug ineffective'? | Clinical Heterogeneity in Acute Symptomatic Seizures due to Autoimmune Encephalitis Related to GAD65 Antibodies.
BACKGROUND
This study aimed to explore the diversity and clinical features of acute symptomatic seizures due to autoimmune encephalitis related to anti-glutamate decarboxylase (GAD) 65 antibodies.
METHODS
... | Fatal | ReactionOutcome | CC BY-NC | 34847555 | 20,189,306 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abnormal faeces'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthenia'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Back pain'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest pain'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Inflammation'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Micturition disorder'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Muscular weakness'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nodule'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rheumatoid vasculitis'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,237,057 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Spinal subarachnoid haemorrhage'. | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | CELECOXIB, LEFLUNOMIDE | DrugsGivenReaction | CC BY | 34847873 | 20,237,057 | 2021-11-30 |
What was the dosage of drug 'CELECOXIB'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | UNKNOWN DOSE | DrugDosageText | CC BY | 34847873 | 20,237,057 | 2021-11-30 |
What was the dosage of drug 'LEFLUNOMIDE'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | UNKNOWN DOSE | DrugDosageText | CC BY | 34847873 | 20,237,057 | 2021-11-30 |
What was the outcome of reaction 'Abnormal faeces'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Anaemia'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Asthenia'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Back pain'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Chest pain'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Inflammation'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Micturition disorder'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Muscular weakness'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Nodule'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,178,028 | 2021-11-30 |
What was the outcome of reaction 'Rheumatoid vasculitis'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,237,057 | 2021-11-30 |
What was the outcome of reaction 'Spinal subarachnoid haemorrhage'? | Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.
BACKGROUND
Spinal subarachnoid haemorrhage is extremely rare in cases of subarachnoid haemorrhage and possesses servere characteristics. Additionally, spinal rheumatoid vasculitis is rare for spinal subarachnoid haemorrhage. The p... | Recovering | ReactionOutcome | CC BY | 34847873 | 20,237,057 | 2021-11-30 |
What is the weight of the patient? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | 36.5 kg. | Weight | CC BY | 34847962 | 20,197,348 | 2021-12-01 |
What was the administration route of drug 'AZELNIDIPINE'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Oral | DrugAdministrationRoute | CC BY | 34847962 | 20,197,348 | 2021-12-01 |
What was the administration route of drug 'FAMOTIDINE'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Oral | DrugAdministrationRoute | CC BY | 34847962 | 20,240,156 | 2021-12-01 |
What was the administration route of drug 'IRSOGLADINE MALEATE'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Oral | DrugAdministrationRoute | CC BY | 34847962 | 20,240,156 | 2021-12-01 |
What was the administration route of drug 'MOSAPRIDE CITRATE DIHYDRATE'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Oral | DrugAdministrationRoute | CC BY | 34847962 | 20,305,900 | 2021-12-01 |
What was the administration route of drug 'MOSAPRIDE CITRATE'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Oral | DrugAdministrationRoute | CC BY | 34847962 | 20,240,156 | 2021-12-01 |
What was the administration route of drug 'SIMVASTATIN'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Oral | DrugAdministrationRoute | CC BY | 34847962 | 20,197,348 | 2021-12-01 |
What was the outcome of reaction 'Atrioventricular block complete'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Recovered | ReactionOutcome | CC BY | 34847962 | 20,197,348 | 2021-12-01 |
What was the outcome of reaction 'Drug interaction'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Recovered | ReactionOutcome | CC BY | 34847962 | 20,197,348 | 2021-12-01 |
What was the outcome of reaction 'Drug level increased'? | A case of complete atrioventricular block with extremely high blood concentration of azelnidipine.
BACKGROUND
Azelnidipine, a dihydropyridine calcium channel blocker (CCB), has less adverse effects (e.g. hot flushes and reflex tachycardia) compared to other dihydropyridine CCBs. Azelnidipine has been reported to reduce... | Recovered | ReactionOutcome | CC BY | 34847962 | 20,278,883 | 2021-12-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine.
Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modali... | CLOFAZIMINE, METHOTREXATE, METHYLPREDNISOLONE, MINOCYCLINE HYDROCHLORIDE, THALIDOMIDE | DrugsGivenReaction | CC BY | 34848113 | 20,884,659 | 2021-11-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine.
Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modali... | CLOFAZIMINE, METHOTREXATE, METHYLPREDNISOLONE, MINOCYCLINE HYDROCHLORIDE, THALIDOMIDE | DrugsGivenReaction | CC BY | 34848113 | 20,884,659 | 2021-11-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine.
Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modali... | METHOTREXATE, METHYLPREDNISOLONE, MINOCYCLINE HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34848113 | 20,908,323 | 2021-11-27 |
What was the administration route of drug 'METHOTREXATE'? | Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine.
Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modali... | Oral | DrugAdministrationRoute | CC BY | 34848113 | 20,884,659 | 2021-11-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal ulcer'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ileus paralytic'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Peripheral sensory neuropathy'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumoperitoneum'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Substance-induced psychotic disorder'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular tachycardia'. | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
What was the administration route of drug 'CARBIDOPA\LEVODOPA'? | Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effe... | Other | DrugAdministrationRoute | CC BY | 34848716 | 20,818,893 | 2021-11-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiotoxicity'. | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34848973 | 20,167,012 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated hepatic disorder'. | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34848973 | 20,167,012 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated renal disorder'. | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34848973 | 20,167,012 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephropathy toxic'. | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34848973 | 20,167,012 | 2021 |
What was the outcome of reaction 'Cardiotoxicity'? | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | Recovered | ReactionOutcome | CC BY-NC | 34848973 | 20,167,012 | 2021 |
What was the outcome of reaction 'Immune-mediated hepatic disorder'? | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | Recovered | ReactionOutcome | CC BY-NC | 34848973 | 20,167,012 | 2021 |
What was the outcome of reaction 'Immune-mediated renal disorder'? | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | Recovered | ReactionOutcome | CC BY-NC | 34848973 | 20,167,012 | 2021 |
What was the outcome of reaction 'Nephropathy toxic'? | Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report.
PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is r... | Recovered | ReactionOutcome | CC BY-NC | 34848973 | 20,167,012 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaphylactic reaction'. | Is the clinical manifestation of anaphylaxis in children influenced by the trigger of reaction?
The number of anaphylaxis diagnoses in children is rising, being still based on the clinical picture.
To determine whether triggers of anaphylaxis influence its clinical characteristics in children and adolescents.
The study... | ACETAMINOPHEN | DrugsGivenReaction | CC BY-NC-SA | 34849125 | 20,104,840 | 2021-10 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.